Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging

Neuroscience Letters

Volumn 528, Issue 2, 2012, Pages 205-209

  Argyriou, Assimina ^a   Dermentzaki, Georgia ^a   Papasilekas, Themistoklis ^a,b   Moraitou, Marina ^c   Stamboulis, Eleftherios ^b   Vekrellis, Kostas ^a   Michelakakis, Helen ^c   Stefanis, Leonidas ^a,b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Institute of Child Health   (Greece)

Author keywords

Alpha synuclein; Gaucher disease; Oligomerization; Parkinson's disease; Red blood cells

Indexed keywords

ALPHA SYNUCLEIN; DIMER; MONOMER;

ADOLESCENT; ADULT; AGED; AGING; ARTICLE; CELL LYSATE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIMERIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; GAUCHER DISEASE; HUMAN; INFANT; MALE; PARKINSON DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGING; ALPHA-SYNUCLEIN; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ERYTHROCYTES; FEMALE; GAUCHER DISEASE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PROTEIN MULTIMERIZATION; YOUNG ADULT;

EID: 84867720975     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.08.069     Document Type: Article

References (25)

1. Barbour R., King K., Anderson J.P., Banducci K., Cole T., Diep L., Fox M., Goldstein J.M., Soriano F., Seubert P., Chilcote T.J. Red blood cells are the major source of alpha-synuclein in blood. Neurodegenerative Diseases 2008, 5:55-59.
2. Brighina L., Prigione A., Begni B., Galbussera A., Andreoni S., Piolti R., Ferrarese C. Lymphomonocyte alpha-synuclein levels in aging and in Parkinson disease. Neurobiology of Aging 2010, 31:884-885.
3. Bultron G., Kacena K., Pearson D., Boxer M., Yang R., Sathe S., Pastores G., Mistry P.K. The risk of Parkinson's disease in type 1 Gaucher disease. Journal of Inherited Metabolic Disease 2010, 33:167-173.
4. Cimen M.Y. Free radical metabolism in human erythrocytes. Clinica Chimica Acta 2008, 390:1-11.
5. Clarke J.T. The glycosphingolipids of human plasma lipoproteins. Canadian Journal of Biochemistry 1981, 59:412-417.
6. Cookson M.R., Van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Experimental Neurology 2008, 209:5-11.
7. Cullen V., Sardi S.P., Ng J., Xu Y.H., Sun Y., Tomlinson J.J., Kolodziej P., Kahn I., Saftig P., Woulfe J., Rochet J.C., Glicksman M.A., Cheng S.H., Grabowski G.A., Shihabuddin L.S., Schlossmacher M.G. Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha synuclein processing. Annals of Neurology 2011, 69:940-953.
8. DePaolo J., Goker-Alpan O., Samaddar T., Lopez G., Sidransky E. The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism. Movement Disorders 2009, 24:1571-1578.
9. Glaros E.N., Kim W.S., Quinn C.M., Won J., Gelissen I., Jessup W., Garner B. Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipoprotein A-I pathway: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator. Journal of Biological Chemistry 2005, 280:24515-24523.
10. Goker-Alpan O., Giasson B.I., Eblan M.J., Nguyen J., Hurtig H.I., Lee V.M., Trojanowski J.Q., Sidransky E. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006, 67:908-910.
11. Guggenbuhl P., Grosbois B., Chalès G. Gaucher disease. Joint, Bone, Spine 2008, 75:116-124.
12. Krishnan S., Chi E.Y., Wood S.J., Kendrick B.S., Li C., Garzon-Rodriguez W., Wypych J., Randolph T.W., Narhi L.O., Biere A.L., Citron M., Carpenter J.F. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry 2003, 42:829-837.
13. Manning-Boĝ A.B., Schüle B., Langston J.W. Alpha-synuclein glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 2009, 30:1127-1132.
14. Martin M., Dotti C.G., Ledesma M.D. Brain cholesterol in normal and pathological aging. Biochimica et Biophysica Acta 2010, 1801:934-944.
15. Mazzulli J.R., Xu Y.H., Sun Y., Knight A.L., McLean P.J., Caldwell G.A., Sidransky E., Grabowski G.A., Krainc D. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52.
16. Moraitou M., Dimitriou E., Zafeiriou D., Reppa C., Marinakis T., Sarafidou J., Michelakakis H. Plasmalogen levels in Gaucher disease. Blood Cells, Molecules, and Diseases 2008, 41:196-199.
17. Neumann J., Bras J., Deas E., O'Sullivan S.S., Parkkinen L., Lachmann R.H., Li A., Holton J., Guerreiro R., Paudel R., Segarane B., Singleton A., Lees A., Hardy J., Houlden H., Revesz T., Wood N.W. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009, 132:1783-1794.
18. Nilsson O., Håkansson G., Dreborg S., Groth C.G., Svennerholm L. Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III. Clinical Genetics 1982, 22:274-279.
19. Prigione A.A., Piazza F., Brighina L., Begni B., Galbussera A., Difrancesco J.C., Andreoni S., Piolti R., Ferrarese C. Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease. Neuroscience Letters 2010, 477:6-10.
20. Sharon R., Bar-Joseph I., Frosch M.P., Walsh D.M., Hamilton J.A., Selkoe D.J. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003, 37:583-595.
21. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., Bar-Shira A., Berg D., Bras J., Brice A., Chen C.M., Clark L.N., Condroyer C., De Marco E.V., Dürr A., Eblan M.J., Fahn S., Farrer M.J., Fung H.C., Gan-Or Z., Gasser T., Gershoni-Baruch R., Giladi N., Griffith A., Gurevich T., Januario C., Kropp P., Lang A.E., Lee-Chen G.J., Lesage S., Marder K., Mata I.F., Mirelman A., Mitsui J., Mizuta I., Nicoletti G., Oliveira C., Ottman R., Orr-Urtreger A., Pereira L.V., Quattrone A., Rogaeva E., Rolfs A., Rosenbaum H., Rozenberg R., Samii A., Samaddar T., Schulte C., Sharma M., Singleton A., Spitz M., Tan E.K., Tayebi N., Toda T., Troiano A.R., Tsuji S., Wittstock M., Wolfsberg T.G., Wu Y.R., Zabetian P.C., Zhao Y., Ziegler S.G. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New England Journal of Medicine 2009, 361:1651-1661.
22. Tokuda T., Qureshi M.M., Ardah M.T., Varghese S., Shehab S.A., Kasai T., Ishigami N., Tamaoka A., Nakagawa M., El-Agnaf O.M. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 65:1766-1772.
23. Vekrellis K., Rideout H.J., Stefanis L. Neurobiology of alpha-synuclein. Molecular Neurobiology 2004, 30:1-21.
24. Vekrellis K., Xilouri M., Emmanouilidou E., Stefanis L. Inducible over-expression of wild type alpha-synuclein in human neuronal cells leads to caspase-dependent nonapoptotic death. Journal of Neurochemistry 2009, 109:1348-1362.
25. Xu Y.H., Sun Y., Ran H., Quinn B., Witte D., Grabowski G.A. Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Molecular Genetics and Metabolism 2011, 102:436-447.